Shanghai Medicilon Inc
SSE:688202
Intrinsic Value
Shanghai Medicilon, Inc. provides outsourced research and development services for pharmaceutical and biotechnology companies through contractual forms. [ Read More ]
The intrinsic value of one
Shanghai Medicilon Inc
stock under the Base Case scenario is
53.18
CNY.
Compared to the current market price of 32.69 CNY,
Shanghai Medicilon Inc
is
Undervalued by 39%.
Shanghai Medicilon Inc's market capitalization is 4.4B CNY.
Shanghai Medicilon Inc stock price is 32.69 CNY.
Shanghai Medicilon Inc stock price (32.69 CNY) is 39% less than its Intrinsic Value (53.18 CNY).
Shanghai Medicilon Inc stock price (32.69 CNY) is 15% less than its DCF Value (38.57 CNY). Open DCF Valuation
Shanghai Medicilon Inc stock price (32.69 CNY) is 52% less than its Relative Value (67.78 CNY). Open Relative Valuation
Shanghai Medicilon Inc.
Shanghai Medicilon Inc's Revenue has dropped by 1% over the past 12 months.
Shanghai Medicilon Inc's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 9%.
Shanghai Medicilon Inc's ROE (Return on Equity) for the past 12 months is positive and is equal to 8%.
Shanghai Medicilon Inc's ROE (Return on Equity) has decreased in the last 3 years from 15% to 8%.
Shanghai Medicilon Inc's Revenue is forecast to grow at a rate of 14% per year over the next 3 years.
Shanghai Medicilon Inc has positive Net Income for the last twelve months.
Shanghai Medicilon Inc has positive Operating Income for the last twelve months.
Shanghai Medicilon Inc's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 23% to 9%.
Shanghai Medicilon Inc has negative Free Cash Flow for the last twelve months.
Shanghai Medicilon Inc has positive three-year average ROE (Return on Equity): 20%. The company is efficient at transforming stockholders' equity into net income.
Shanghai Medicilon Inc has positive three-year average ROIC (Return on Invested Capital): 22%. The company is efficient at using invested capital to generate operating income.
Shanghai Medicilon Inc has positive Gross Profit for the last twelve months.
Shanghai Medicilon Inc's Revenue has been growing by an exceptional 41% per year for the last 3 years.
Shanghai Medicilon Inc has negative Net Debt. This means that the company has more cash and short-term investments (1B CNY) than debt (470m CNY).
Shanghai Medicilon Inc's short-term assets (2B CNY) exceed its short-term liabilties (766m CNY).
Shanghai Medicilon Inc's D/E (Debt to Equity) is very low and is equal to 0.18.
Shanghai Medicilon Inc's long-term assets (4B CNY) exceed its long-term liabilties (880m CNY).
Shanghai Medicilon Inc's Altman Z-Score is very high and is equal to 8.19.
Valuation Backtest
Shanghai Medicilon Inc
Run backtest to discover the historical profit from buying and selling
Shanghai Medicilon Inc
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Shanghai Medicilon Inc
Balance Sheet Decomposition
Shanghai Medicilon Inc
| Current Assets | 2.2B |
| Cash & Short-Term Investments | 1.1B |
| Receivables | 836.6m |
| Other Current Assets | 245.2m |
| Non-Current Assets | 1.3B |
| Long-Term Investments | 60.1m |
| PP&E | 797.8m |
| Intangibles | 288.8m |
| Other Non-Current Assets | 187.1m |
| Current Liabilities | 766m |
| Accounts Payable | 175.4m |
| Accrued Liabilities | 50.4m |
| Short-Term Debt | 452.8m |
| Other Current Liabilities | 87.5m |
| Non-Current Liabilities | 114.2m |
| Long-Term Debt | 17m |
| Other Non-Current Liabilities | 97.2m |
Earnings Waterfall
Shanghai Medicilon Inc
|
Revenue
|
1.6B
CNY
|
|
Cost of Revenue
|
-1.1B
CNY
|
|
Gross Profit
|
500.7m
CNY
|
|
Operating Expenses
|
-324.3m
CNY
|
|
Operating Income
|
176.3m
CNY
|
|
Other Expenses
|
-1.3m
CNY
|
|
Net Income
|
175m
CNY
|
Free Cash Flow Analysis
Shanghai Medicilon Inc
Profitability Score
Profitability Due Diligence
Shanghai Medicilon Inc's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
Shanghai Medicilon Inc's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shanghai Medicilon Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Shanghai Medicilon Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shanghai Medicilon Inc
Shareholder Return
Price
Shanghai Medicilon Inc
| Average Annual Return | 74.93% |
| Standard Deviation of Annual Returns | 115.51% |
| Max Drawdown | -94% |
| Market Capitalization | 4.4B CNY |
| Shares Outstanding | 134 673 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Shanghai Medicilon Inc
Country
Industry
Market Cap
Dividend Yield
Description
Shanghai Medicilon, Inc. provides outsourced research and development services for pharmaceutical and biotechnology companies through contractual forms. The company is headquartered in Shanghai, Shanghai and currently employs 2,440 full-time employees. The company went IPO on 2019-11-05. The firm is committed to providing a full range of new drug research and development (R&D) services for pharmaceutical enterprises and other new drug R&D institutions. The firm's main businesses include drug discovery and pharmaceutical research and preclinical research. The drug discovery and pharmaceutical research mainly include services such as compound synthesis and screening, active pharmaceutical ingredients (API) and preparation technology research. The preclinical research services mainly include pharmacodynamics research, pharmacokinetics research, toxicology research and other services. The firm provides services for domestic and foreign customers such as the United States, Europe, Japan and South Korea.
Contact
IPO
Employees
Officers
The intrinsic value of one
Shanghai Medicilon Inc
stock under the Base Case scenario is
53.18
CNY.
Compared to the current market price of 32.69 CNY,
Shanghai Medicilon Inc
is
Undervalued by 39%.
You don't have any saved screeners yet
